A new treatment may bring back hope for cancer patients who had become resistant to immunotherapy, a new study from the United Kingdom suggests.
Immunotherapy is a mode of cancer treatment that aims to boost the body’s own immune system to target and kill cancer cells and is employed when other options such as surgery, radiotherapy, or chemotherapy, have failed.
But some patients have cancerous tumors that progress and become resistant to immunotherapy.
The study, led by researchers at The Institute of Cancer Research (ICR), London and The Royal Marsden NHS Foundation Trust, examined a combination treatment comprising of pembrolizumab—an immunotherapy drug—and a novel experimental drug called guadecitabine….